HBT1

HBT1, also written HBT-1, is an experimental AMPA-receptor modulator discussed for memory, clearer thinking and vivid perception. The human discussion is a small, conflicting anecdotal record; it does not establish a reliable benefit or a safe way to use it.

What HBT1 is

• A small molecule studied at AMPA receptors. AMPA receptors help nerve cells respond to glutamate. HBT1 is a positive allosteric modulator: it strengthens receptor responses under particular laboratory conditions. Its chemical structure is not a peptide, despite appearing in peptide-oriented catalogs. Animal context
• BDNF is part of the interest, not a demonstrated human benefit. An early discussion focused on laboratory production of brain-derived neurotrophic factor, a protein involved in nerve-cell function. That is different from showing that a person learns more, repairs brain damage or treats depression. Reddit / r/Nootropics Animal context

What people report

• Clearer recall, sharper vision and calm. The AMA reports digit span rising from 9 to 12 and reaction time falling from about 325 to 190–200 milliseconds. Repeated, unblinded tests with other compounds do not establish causation. Personal report
• No noticeable benefit is also reported. Another participant, gintrux, reported feeling nothing despite trying substantial intranasal amounts without a stack. A positive account and a negative account cannot establish how likely a benefit is. Personal report

How the comparisons fit

• AMPA compounds need separate practical answers. A similar target is not evidence of interchangeable effects. HBT1’s receptor finding belongs to this molecule; another compound’s dose or half-life cannot fill its missing human evidence. Animal context
• Semax and racetam comparisons describe hopes, not equivalence. The later identity thread compares HBT-1 with familiar cognition compounds. It supplies no head-to-head test. A similar goal such as less brain fog does not mean the same chemistry or practical use. Reddit / r/Nootropics

Doses people discuss

All amounts are self-reported milligrams of unverified material. There is no established community working range here.

• About 500 mg total over 24 hours in one AMA. The author described cumulative intranasal use, with little effect at earlier 5–50 mg amounts. Oral and sublingual attempts reportedly did nothing; their amounts were not specified. This is not a single-dose recommendation. Personal report
• About 200 mg one day and 450 mg the next in the null account. gintrux’s edit gives those intranasal amounts after an initial report of about 70 mg over three hours. These are stages of one person’s account, not three independent experiments or a validated dose ladder. Personal report

Half-life

• No reliable community half-life identified. The inspected discussions do not provide a measured clearance value or a traceable numerical estimate. Half-life means how quickly the amount in the body falls; it cannot be inferred from a remembered benefit. Reddit / r/Nootropics Reddit / r/Nootropics

Onset: when a change begins

• No dependable onset clock. The null reporter noticed nothing during an initial three-hour experiment. That is an observation window without benefit, not a three-hour onset. The discussion does not establish when a single dose should begin working. Personal report

Duration: how long it feels different

• Next-day residual effects in the AMA. The strongest experience reportedly faded by the following day. Residual changes do not establish a single-dose duration or lasting improvement. Personal report

Cycles and time off

• No established on/off schedule. The inspected material concerns exploratory use and questions, not a sustained, documented cycle with follow-up. It gives no sound basis for a weekly routine, tolerance reset or safe course length. Reddit / r/Nootropics Personal report

Good to know

• Nasal and possible airway discomfort were reported. The AMA describes unpleasant residue and suspected powder inhalation. Perceived cognitive benefit does not offset these adverse experiences. Personal report
• Route explanations remain speculation. Proposed stomach-breakdown and brain-entry mechanisms, including speculation about prior nasal damage, establish neither absorption nor route safety. Personal report Personal report
• Low agonistic activity does not establish safety in people. A laboratory finding about receptor activation cannot certify freedom from seizures, neurotoxicity or drug interactions. A later commenter’s seizure warning is a concern, not a documented HBT1 seizure case or a known threshold. Animal context Reddit / r/Nootropics

From community discussion

• The enthusiastic author still judged it poor value. Expense, impractical amounts and uncomfortable administration outweighed the reported benefit for this author. Personal report
• The same author disclosed several co-compounds. Methylphenidate, an unnamed NMDA antagonist, NAC and magnesium appeared in the original account; a reply added NSI-189, PRL-8-53 and nooglutyl. This is one confounded account, not evidence that a combination is compatible. Personal report Personal report
• Nonresponse has unresolved explanations. gintrux wondered about product age and delivery, but neither explanation was tested. The absence of a stack is useful context; it does not resolve whether identity, exposure or individual response explains the disagreement. Personal report
• Later discussion repeats the earlier story. The 2022 identity thread links back to the 2020 AMA. Its additional questions and opinions are useful context, but they do not add another person with the same positive outcome. The earlier discovery thread likewise contains planned experimentation rather than a completed positive report. Reddit / r/Nootropics Reddit / r/Nootropics

What the laboratory evidence adds

• A receptor-binding finding, not a human trial. The original study abstract reproduced by RCSB describes glutamate-dependent binding, little direct receptor activation in primary neurons and a BDNF response without a marked decline at higher tested concentrations. The structural record concerns an isolated receptor domain; its human-protein label does not mean human volunteers took HBT1. Animal context